OBJECTIVE: Leptin is an adipocyte secreted hormone and an important regulator of neuroendocrine, metabolic, and immune function. Both r-metHuLeptin and IGF1 administration result in reduced central adipose tissue in subjects with highly active antiretroviral therapy-induced metabolic syndrome (HAART-MS) but whether the effects of leptin are mediated through increasing IGF levels remains unknown. METHODS: To assess whether r-metHuLeptin improves the HAART-MS by regulating circulating IGF and IGFBPs, we first conducted a cross-sectional study of 118 men and women with HIV infection and >6 months of exposure to antiretroviral medications to examine any association between circulating IGF1 and leptin levels. We also performed a randomized, double-blinded, placebo-controlled, crossover trial of recombinant human leptin (r-metHuLeptin) administration to seven HIV positive men with lipoatrophy and leptin deficiency (leptin <3 ng/ml) related to antiretroviral medication use. RESULTS: In the observational study, leptin levels were inversely associated with circulating IGF1 levels after adjusting for age and gender (r=0.27 P=0.002), but this inverse association became non-significant after adjustment for % body fat and exercise. In the interventional leptin study, leptin levels increased significantly during r-metHuLeptin treatment (from 1.34+/-0.20 ng/ml at baseline to 17+/-5.05 ng/ml after 8 weeks P=0.046) and metabolic parameters improved including reduced fasting insulin levels and reduced homeostasis model assessment-insulin resistance (HOMA-IR). Despite the increase in circulating leptin levels, there was no change in IGF1, IGF2, free IGF1, or IGF-binding proteins during the 2-month treatment period. CONCLUSION: The effects of r-metHuLeptin in patients with HAART-MS are not mediated through increasing IGF or IGFBP levels.
RCT Entities:
OBJECTIVE:Leptin is an adipocyte secreted hormone and an important regulator of neuroendocrine, metabolic, and immune function. Both r-metHuLeptin and IGF1 administration result in reduced central adipose tissue in subjects with highly active antiretroviral therapy-induced metabolic syndrome (HAART-MS) but whether the effects of leptin are mediated through increasing IGF levels remains unknown. METHODS: To assess whether r-metHuLeptin improves the HAART-MS by regulating circulating IGF and IGFBPs, we first conducted a cross-sectional study of 118 men and women with HIV infection and >6 months of exposure to antiretroviral medications to examine any association between circulating IGF1 and leptin levels. We also performed a randomized, double-blinded, placebo-controlled, crossover trial of recombinant humanleptin (r-metHuLeptin) administration to seven HIV positive men with lipoatrophy and leptin deficiency (leptin <3 ng/ml) related to antiretroviral medication use. RESULTS: In the observational study, leptin levels were inversely associated with circulating IGF1 levels after adjusting for age and gender (r=0.27 P=0.002), but this inverse association became non-significant after adjustment for % body fat and exercise. In the interventional leptin study, leptin levels increased significantly during r-metHuLeptin treatment (from 1.34+/-0.20 ng/ml at baseline to 17+/-5.05 ng/ml after 8 weeks P=0.046) and metabolic parameters improved including reduced fasting insulin levels and reduced homeostasis model assessment-insulin resistance (HOMA-IR). Despite the increase in circulating leptin levels, there was no change in IGF1, IGF2, free IGF1, or IGF-binding proteins during the 2-month treatment period. CONCLUSION: The effects of r-metHuLeptin in patients with HAART-MS are not mediated through increasing IGF or IGFBP levels.
Authors: Jennifer H Lee; Jean L Chan; Epaminondas Sourlas; Vassilios Raptopoulos; Christos S Mantzoros Journal: J Clin Endocrinol Metab Date: 2006-04-24 Impact factor: 5.958
Authors: G Sonia Nagy; Sotirios Tsiodras; Lizabeth D Martin; Anchalee Avihingsanon; Alina Gavrila; William C Hsu; Adolf W Karchmer; Christos S Mantzoros Journal: Clin Infect Dis Date: 2003-03-05 Impact factor: 9.079
Authors: Julio Licinio; Sinan Caglayan; Metin Ozata; Bulent O Yildiz; Patricia B de Miranda; Fiona O'Kirwan; Robert Whitby; Liyin Liang; Pinchas Cohen; Shalender Bhasin; Ronald M Krauss; Johannes D Veldhuis; Anthony J Wagner; Alex M DePaoli; Samuel M McCann; Ma-Li Wong Journal: Proc Natl Acad Sci U S A Date: 2004-03-09 Impact factor: 11.205
Authors: Jean L Chan; Kathleen Heist; Alex M DePaoli; Johannes D Veldhuis; Christos S Mantzoros Journal: J Clin Invest Date: 2003-05 Impact factor: 14.808
Authors: Corrine K Welt; Jean L Chan; John Bullen; Robyn Murphy; Patricia Smith; Alex M DePaoli; Aspasia Karalis; Christos S Mantzoros Journal: N Engl J Med Date: 2004-09-02 Impact factor: 91.245
Authors: Jean L Chan; Giuseppe Matarese; Greeshma K Shetty; Patricia Raciti; Iosif Kelesidis; Daniela Aufiero; Veronica De Rosa; Francesco Perna; Silvia Fontana; Christos S Mantzoros Journal: Proc Natl Acad Sci U S A Date: 2006-05-19 Impact factor: 11.205
Authors: Christos S Mantzoros; Faidon Magkos; Mary Brinkoetter; Elizabeth Sienkiewicz; Tina A Dardeno; Sang-Yong Kim; Ole-Petter R Hamnvik; Anastasia Koniaris Journal: Am J Physiol Endocrinol Metab Date: 2011-07-26 Impact factor: 4.310
Authors: Tina A Dardeno; Sharon H Chou; Hyun-Seuk Moon; John P Chamberland; Christina G Fiorenza; Christos S Mantzoros Journal: Front Neuroendocrinol Date: 2010-06-17 Impact factor: 8.606